Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.

@article{Nicholson1991EpidermalGF,
  title={Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.},
  author={Steve Nicholson and J{\'e}r{\^o}me Richard and Christine Sainsbury and P. Halcrow and P. Kelly and Brian Angus and Clare Wright and J. Henry and John Richard Farndon and A. L. Harris},
  journal={British Journal of Cancer},
  year={1991},
  volume={63},
  pages={146 - 150}
}
More accurate criteria are required for the selection of patients with node-negative breast cancer for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231 patients with operable breast cancer followed for up to 6 years after surgery. The… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…